David Russell‐Jones

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Simon Heller, John B. Buse, Miles Fisher et al. · The Lancet · 2012 · 401 citations

Type 1, Diabetes Management, Insulin Degludec +7

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

David Russell‐Jones, Robert Cuddihy, M Hanefeld et al. · Diabetes Care · 2011 · 336 citations · Full text

The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients

James Gibney, Jennifer Wallace, T.J. Spinks et al. · The Journal of Clinical Endocrinology & Metabolism · 1999 · 313 citations

Human Growth, Gynecology, Hyperlipidemia +17

Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes

Philip Home, Paul B. Bartley, David Russell‐Jones et al. · Diabetes Care · 2004 · 256 citations · Full text

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 218 citations · Full text